(Press-News.org) WHAT:
Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.
The two analyses were presented at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C. The health benefits talk was presented by Beatriz Grinsztejn, M.D., HPTN site investigator for the Instituto de Pesquisa Clinica Evandro Chagas in Brazil. The cost-effectiveness talk was given by Kenneth A. Freedberg, M.D., MSc, an associate professor of medicine at Harvard Medical School and director of the Program in Epidemiology and Outcomes Research at the Harvard Medical School's Division of AIDS.
Initial results from the HPTN 052 study, announced in 2011, demonstrated that earlier use of antiretrovirals by HIV-infected heterosexuals partnered with uninfected individuals (serodiscordant couples) reduced HIV transmission by 96 percent. In two years of follow-up analysis of 1,761 HIV-infected study participants, researchers compared those who delayed antiretroviral treatment until their CD4+ T-cell counts were an average of 230 cells/ per cubic millimeter (mm³) with those who began antiretroviral treatment sooner (an average CD4 level of 440 cells/ mm³). The delayed group experienced a shorter time to a primary clinical event, including AIDS-defining disease and all types of tuberculosis. In total, there were 91 primary clinical events in the delayed treatment group versus 71 in the immediate group. This included 71 cases of AIDS-defining disease in the delayed treatment group versus 49 in the immediate group, and 34 cases of tuberculosis in the delayed group versus 17 in the immediate group. The trial provides evidence that earlier antiretroviral treatment among the HIV-infected provides significant health benefits.
In a separate modeling analysis designed to predict the clinical impact, costs and cost-effectiveness of the earlier antiretroviral treatment strategy, researchers compared the delayed treatment (CD4 counts of less than 250 cells/mm³) versus earlier treatment (350-550 cells/ mm³) data in South Africa and India. The two countries were selected to show how regional economic differences may or may not affect the conclusions. The researchers designated earlier treatment to be "very cost effective" if its cost-effectiveness ratio was less than one times per capita gross domestic product (GDP). Earlier treatment was deemed "cost effective" if its cost-effectiveness ratio was less than three times per capita GDP. The GDP was set at $8,100 for South Africa and $1,400 for India. Using this model, they found that in both South Africa and India early ART increases patient survival, prevents costly opportunistic infections—partially offsetting the costs of treatment—averts HIV transmission, and is cost-effective within a five-year span and very cost-effective over a lifetime.
###The HPTN 052 study and its follow-up analyses were funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. They were conducted by the NIH-funded HIV Prevention Trials Network.
WHO:
NIAID Director Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D., director of NIAID's Division of AIDS, are available to comment.
CONTACT:
To schedule interviews, please contact Kathy Stover, (301) 402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness
2012-07-28
ELSE PRESS RELEASES FROM THIS DATE:
Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
2012-07-28
Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.
To date, treatments for diabetic retinopathy, the leading cause of blindness among working-age Americans, have been aimed largely at one of those mechanisms.
In diabetic retinopathy, ...
Tumor cells' inner workings predict cancer progression
2012-07-28
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL). The assay method distinguishes features of leukemia cells that indicate whether the disease will be aggressive or slow-moving, a key factor in when and how patients are treated.
The findings are published in the July 26, 2012 First Edition online issue of Blood.
The progression of CLL is highly variable, dependent upon the rate and ...
NASA sees organizing tropical low pressure area near the Philippines
2012-07-28
A low pressure system in the western North Pacific has caught the eye of forecasters and several satellites as it continues to organize. NASA's Terra satellite captured a view of System 93W's clouds as they continue to appear more organized.
System 93W appears poised to become tropical storm Saola over the next two days if the organization continues. At 1400 UTC (10 a.m. EDT/U.S.; 10 p.m. Asia/Manila local time) System 93W had maximum sustained winds near 20 knots (23 mph/37 kmh). It was located about 395 nautical miles (454.6 miles/731.5 km) east-southeast of Manila, ...
UCLA researchers discover that fluoxetine -- a.k.a., Prozac -- is effective as an anti-viral
2012-07-28
UCLA researchers have come across an unexpected potential use for fluoxetine – commonly known as Prozac – which shows promise as an antiviral agent. The discovery could provide another tool in treating human enteroviruses that sicken and kill people in the U.S. and around the world.
Human enteroviruses are members of a genus containing more than 100 distinct RNA viruses responsible for various life threatening infections, such as poliomyelitis and encephalitis. While immunization has all but eliminated the poliovirus, the archetype for the genus, no antiviral drugs ...
Martian polygons and deep-sea polygons on Earth: More evidence for ancient Martian oceans?
2012-07-28
Boulder, Colorado, USA - Debate over the origin of large-scale polygons (hundreds of meters to kilometers in diameter) on Mars remains active even after several decades of detailed observations. Similarity in geometric patterns on Mars and Earth has long captured the imagination. In this new article from GSA Today, geologists at The University of Texas at Austin examine these large-scale polygons and compare them to similar features on Earth's seafloor, which they believe may have formed via similar processes.
Understanding these processes may in turn fuel support for ...
Think you're a comic genius? Maybe you're just overconfident
2012-07-28
TALLAHASSEE, Fla. Knock, knock! Who's there? Cows go. Cows go who? No, cows go moo!
OK, OK. So it's not a side-slapper — especially if the teller has zero sense of comic timing. But most likely the person sharing the joke over the water cooler thinks he or she is pretty funny.
No matter how badly the joke is told, it will sometimes elicit a few polite laughs.
Why?
Because social norms make us averse to providing negative feedback, says Joyce Ehrlinger, a Florida State University assistant professor of psychology whose latest laboratory research recreated everyday ...
World Hepatitis Day - EASL calls on the United Nations to join the effort to tackle viral hepatitis
2012-07-28
Geneva, 28th July 2012 – Marking World Hepatitis Day, the European Association for the Study of the Liver (EASL) calls on the different organizations which make up the United Nations systems to take action to fight against Viral Hepatitis (Hepatitis B and C), a potentially fatal infection of the liver which affects 500 million people. Viral hepatitis is the cause of death of over one million people a year and, around the world, one in every 3 people has been exposed to either the Hepatitis B virus or the Hepatitis C virus. Even more worrying, those infected do not know ...
Smart Mobile Solutions Announces Its New Notepad Mobile App - Skinny Note!
2012-07-28
Smart Mobile Solutions is proud to announce it is releasing its newest app for mobile devices - Skinny Note!
Skinny Note is an easy to use and fun notepad application for Android devices. It allows users to create text notes, diary notes, check lists, to do lists, reminder lists, and much more, all in a fun and easy-to-use interface. Some of Skinny Note's notable features include:
- Customize notes through font size and background color
- Filter notes based on color and/or type
- Set up notifications for specific notes
- Categorize notes based on colors and names
- Sort ...
5W Public Relations Named PR Agency of Record For SNAP Infusion
2012-07-28
5W Public Relations a leading NY PR Agency is pleased to announce the addition of SNAP Infusion to its growing roster of clients. 5W Public Relations will execute a comprehensive public relations program designed to increase awareness of the company with the goal of becoming recognized as the category leader.
"We are thrilled to be working with SNAP Infusion's line of SUPERCANDY ," said Ronn Torossian, CEO of 5WPR. "Given our extensive experience creating and implementing successful public relations programs for other consumer products, we are confident ...
Panel on Investment Opportunities with VCs at CNS Partnering meeting Sept 13-14, San Francisco
2012-07-28
Novo Ventures, Third Rock Ventures, Abingworth Management and TPG Biotech will speak in a Panel Discussion on "Investment Opportunities with Venture Capital" at the 5th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 13-14, 2012.
Representatives from leading venture capital companies are:
Heath Lukatch, Ph.D., Partner, Novo Ventures
Kiran Reddy, M.D., Principal, Third Rock Ventures
Ken Haas, Venture Partner, Abingworth Management
Eran Nadav, Ph.D MBA, Managing Director, TPG Biotech
The panel discussion will focus ...